TheHIV therapeutics market and it is poised togrow by USD 2.44 billion during 2019-2023, progressing at a CAGR of almost 2%during the forecast period. The report offers an up-to-date analysis regardingthe current market scenario, latest trends and drivers, and the overall marketenvironment.
Technavio suggests three forecast scenarios (optimistic, probable, andpessimistic) considering the impact of COVID-19. Please Request Latest Free SampleReport on COVID-19 Impact
The market is fragmented, and the degree of fragmentation willaccelerate during the forecast period. AbbVie Inc., Boehringer IngelheimInternational GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GileadSciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., LupinLtd., Merck & Co. Inc., Mylan NV, Pfizer Inc., and Teva PharmaceuticalIndustries Ltd. are some of the major market participants. Although the growingawareness about HIV will offer immense growth opportunities, the high cost ofantiretroviral therapies will challenge the growth of the market participants.To make the most of the opportunities, market vendors should focus more on thegrowth prospects in the fast-growing segments, while maintaining their positionsin the slow-growing segments.
The growing awareness about HIV has been instrumental in driving thegrowth of the market. However, the high cost of antiretroviral therapies mighthamper market growth.
HIV Therapeutics Market 2019-2023 : Segmentation
HIV Therapeutics Market is segmented as below:
· Combination Therapy
· Reverse Transcriptase Inhibitors
· Protease Inhibitors
· Fusion Inhibitors
· Integrase Inhibitors
· Coreceptor Antagonists
· Geographic Landscape
· North America
HIV Therapeutics Market 2019-2023 : Scope
Technavio presents a detailed picture of the market by the way of study,synthesis, and summation of data from multiple sources. Our HIV therapeutics market reportcovers the following areas:
· HIV Therapeutics Market size
· HIV Therapeutics Market trends
· HIV Therapeutics Market industry analysis
This study identifies the advances in diagnostic testing for HIV as oneof the prime reasons driving the HIV therapeutics market growth during the nextfew years.
HIV Therapeutics Market 2019-2023 : Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the HIVTherapeutics Market, including some of the vendors such as AbbVie Inc.,Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F.Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson& Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, PfizerInc., and Teva Pharmaceutical Industries Ltd. Backed with competitiveintelligence and benchmarking, our research reports on the HIV TherapeuticsMarket are designed to provide entry support, customer profile and M&As aswell as go-to-market strategy support.